← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Interleukin inhibitors
basiliximab
L04AC02
Forms & Strengths
- Injection: 10mg, 20mg
- Solution for infusion: 10mg/5mL, 20mg/5mL
Adult Dosing
- 20mg IV on day 0 and day 4 post-transplant
- Dose adjusted based on patient weight for kidney transplant
Pediatric Dosing
- Dose based on patient weight: 12mg/m^2 IV on day 0 and day 4
- Maximum dose: 20mg
Indications
- Prevention of acute rejection in kidney transplant patients
- Use in combination with other immunosuppressants
Mechanism of Action
- Binds to interleukin-2 receptor alpha-chain (CD25) on T-cell surface
- Inhibits T-cell activation and proliferation
- Prevents graft rejection by reducing immune response
Contraindications
- Hypersensitivity to basiliximab or murine proteins
- History of allergy to other monoclonal antibodies
Adverse Reactions
- Hypersensitivity reactions
- Anaphylaxis
- Cytokine release syndrome
- Increased risk of infections
Drug Interactions
- Concomitant use with other immunosuppressants may increase risk of infections
- Avoid use with live vaccines
- Monitor for signs of infection or rejection with concomitant use of corticosteroids
Curated Content: Needs Vetting Before Put to Clinical Use